No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACHV240816C5000
- 0.45
- +0.31+221.43%
15min DelayClose Jul 23 15:59 ET
0.45High0.45Low
0.45Open0.14Pre Close5 Volume71 Open Interest5.00Strike Price225.00Turnover109.52%IV6.03%PremiumAug 16, 2024Expiry Date0.14Intrinsic Value100Multiplier24DDays to Expiry0.31Extrinsic Value100Contract SizeAmericanOptions Type0.5992Delta0.2665Gamma7.91Leverage Ratio-0.0120Theta0.0016Rho4.74Eff Leverage0.0051Vega
Intraday
- 5D
- Daily
News
JonesTrading Maintains Achieve Life(ACHV.US) With Buy Rating, Maintains Target Price $20
JonesTrading Keeps Their Buy Rating on Achieve Life Sciences (ACHV)
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
With 64% Ownership of the Shares, Achieve Life Sciences, Inc. (NASDAQ:ACHV) Is Heavily Dominated by Institutional Owners
Express News | Achieve Life Sciences Joins U.S. Russell 3000 And Russell Microcap Indexes
Achieve Life Sciences Announces Addition to the U.S. Russell 3000 and Russell Microcap Indexes
Comments
$Achieve Life(ACHV.US$
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
$Achieve Life(ACHV.US$
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
1
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Read more